116 related articles for article (PubMed ID: 11052785)
21. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.
Underwood DC; Bochnowicz S; Osborn RR; Kotzer CJ; Luttmann MA; Hay DW; Gorycki PD; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):988-95. PubMed ID: 9864284
[TBL] [Abstract][Full Text] [Related]
22. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
Muise ES; Chute IC; Claveau D; Masson P; Boulet L; Tkalec L; Pon DJ; Girard Y; Frenette R; Mancini JA
Biochem Pharmacol; 2002 Apr; 63(8):1527-35. PubMed ID: 11996895
[TBL] [Abstract][Full Text] [Related]
23. Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
Bioorg Med Chem Lett; 2001 Jan; 11(1):33-7. PubMed ID: 11140727
[TBL] [Abstract][Full Text] [Related]
24. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
[TBL] [Abstract][Full Text] [Related]
25. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway.
Robichaud A; Savoie C; Stamatiou PB; Tattersall FD; Chan CC
Neuropharmacology; 2001; 40(2):262-9. PubMed ID: 11114405
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of photoreactive phosphatidic acid analogues displaying activatory properties on cyclic AMP-phosphodiesterases. Photoaffinity labeling of an isoform of phosphodiesterase.
Picq M; Huang Y; Lagarde M; Doutheau A; Nemoz G
J Med Chem; 2002 Apr; 45(8):1678-85. PubMed ID: 11931622
[TBL] [Abstract][Full Text] [Related]
27. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
28. First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives.
Provins L; Christophe B; Danhaive P; Dulieu J; Durieu V; Gillard M; Lebon F; Lengelé S; Quéré L; van Keulen B
Bioorg Med Chem Lett; 2006 Apr; 16(7):1834-9. PubMed ID: 16439121
[TBL] [Abstract][Full Text] [Related]
29. Bronchoprotective effect of an intrabronchial administration of cilostazol powder and a nebulized PDE1 and PDE4 inhibitor KF19514 in guinea pigs.
Fujimura M; Tachibana H; Myou S; Kita T; Matsuda T
Int Arch Allergy Immunol; 1998 Jul; 116(3):220-7. PubMed ID: 9693270
[TBL] [Abstract][Full Text] [Related]
30. PDE IV as a target for anti-asthmatic therapy.
O'Brien C
Mol Med Today; 1997 Sep; 3(9):368-9. PubMed ID: 9302684
[No Abstract] [Full Text] [Related]
31. Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity.
Ferrari F; Mennuni L; Caselli G; Zanelli T; Makovec F
Eur J Pharmacol; 2004 Nov; 504(3):223-33. PubMed ID: 15541426
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and SAR of a novel, potent and structurally simple LTD4 antagonist of the quinoline class.
von Sprecher A; Gerspacher M; Beck A; Kimmel S; Wiestner H; Anderson GP; Niederhauser U; Subramanian N; Bray MA
Bioorg Med Chem Lett; 1998 Apr; 8(8):965-70. PubMed ID: 9871521
[TBL] [Abstract][Full Text] [Related]
33. Orally active PDE4 inhibitor with therapeutic potential.
Ochiai H; Ohtani T; Ishida A; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Eur J Med Chem; 2004 Jul; 39(7):555-71. PubMed ID: 15236836
[TBL] [Abstract][Full Text] [Related]
34. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
35. The potential of PDE4 inhibitors in asthma or COPD.
Spina D
Curr Opin Investig Drugs; 2000 Oct; 1(2):204-13. PubMed ID: 11249575
[TBL] [Abstract][Full Text] [Related]
36. Benzofuran based PDE4 inhibitors.
McGarry DG; Regan JR; Volz FA; Hulme C; Moriarty KJ; Djuric SW; Souness JE; Miller BE; Travis JJ; Sweeney DM
Bioorg Med Chem; 1999 Jun; 7(6):1131-9. PubMed ID: 10428384
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and anti-tubulin activity of a 3'-(4-azidophenyl)-3'-dephenylpaclitaxel photoaffinity probe.
Spletstoser JT; Flaherty PT; Himes RH; Georg GI
J Med Chem; 2004 Dec; 47(26):6459-65. PubMed ID: 15588080
[TBL] [Abstract][Full Text] [Related]
38. 2,1,3-Benzothiadiazine derivatives: synthesis and screening versus PDE4 enzyme.
Tait A; Luppi A; Avallone R; Baraldi M
Farmaco; 2005 Aug; 60(8):653-63. PubMed ID: 15963514
[TBL] [Abstract][Full Text] [Related]
39. Assessing the emetic potential of PDE4 inhibitors in rats.
Robichaud A; Savoie C; Stamatiou PB; Lachance N; Jolicoeur P; Rasori R; Chan CC
Br J Pharmacol; 2002 Jan; 135(1):113-8. PubMed ID: 11786486
[TBL] [Abstract][Full Text] [Related]
40. Effect of baicalin on tracheal permeability in ovalbumin (OA)-sensitized guinea pigs.
Liaw J; Gau YY; Chao YC
Pharm Res; 1999 Oct; 16(10):1653-7. PubMed ID: 10554113
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
